Sponsor Dossier
Ipca Pharma
Sponsor Dossier for Ipca Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: A-CITALOPRAM
- Brand: A-IBUPROFEN
- Brand: AMICHLOR
- Brand: AMIDEP
- Brand: AMITRIPTYLINE
- Brand: ATEN
- Brand: BESIDEP
- Brand: BUTAFEN
About
Ipca Pharma is an Australian Private Company with ABN 66100362258, registered in Victoria. The entity is active and registered for GST from 1 May 2002.
Portfolio
Ipca Pharma has 113 brands on the ARTG, of which 18 are indexable and 17 carry a Product Information document. 2 brands are PBS-listed, 0 have a PBAC outcome on record, and 0 have an AusPAR on record. Notable brands include A-CITALOPRAM, A-IBUPROFEN, AMICHLOR, AMIDEP, AMITRIPTYLINE, ATEN, BESIDEP, BUTAFEN, C-PARACETAMOL, CIPLA, CIPROFLOXACIN-BL, CLOIPCA.
Therapeutic focus
— Cardiology: 29 brands — Psychiatry: 26 brands — Pain Management: 21 brands — Infectious Disease: 8 brands — Neurology: 7 brands — Endocrinology: 6 brands — Oncology: 5 brands — Gastroenterology: 4 brands — Musculoskeletal: 3 brands — Renal: 2 brands — ["Immunology","Infectious Disease"]: 1 brand — Immunology: 1 brand
PBS footprint
2 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.